Navigation Links
R&D Magazine Selects Xoft Axxent(R) Electronic Brachytherapy System as Editor's Choice Innovation Award Winner
Date:3/18/2009

Xoft Axxent(R) Miniature Brachytherapy X-ray Source Recognized

as Most Innovative New Product of the Year

SUNNYVALE, Calif., March 18 /PRNewswire/ -- Xoft, Inc. today announced that R&D Magazine selected the Axxent(R) High Dose Rate (HDR) X-ray Source as Editor's Choice Most Innovative New Product of 2008. The award was announced at the recent R&D 100 Awards ceremony, where the Xoft system was recognized as one of the year's most technologically significant products. Established by the editors of R&D Magazine in 1963, the R&D 100 Awards are designed to recognize significant technological achievements and products that leapfrog current technology and that provide simple, elegant solutions to complex or long-standing technical or practical problems.

"Over the years, R&D Magazine has recognized innovation and impact from products and technologies that have gone on to become household names, such as the ATM, the fax machine, the Kodak photo CD, HDTV and the Nicoderm anti-smoking patch. Being recognized by the editors of this prestigious R&D Magazine as the most innovative new product is a tremendous honor," said Paul Lovoi PhD, CTO and co-founder of Xoft. "This further validates that the Axxent miniature X-ray source is a fundamentally new way to deliver therapeutic radiation - one that we believe is the enabling technology for many generations of increasingly more sophisticated, accurate, and accessible radiation treatment systems."

As a platform technology, the Axxent System addresses a variety of oncological and non-oncological indications. The Axxent System delivers non-radioactive therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue. Designed to deliver electronic, X-ray-based radiation treatment, the proprietary Axxent treatment platform can be used in many clinical settings. Treatment can be performed without the need for a shielded room, allowing the radiation oncologist and other medical personnel to be present during treatment delivery and minimizing patient anxiety. As a result, tens of thousands of patients annually will have greater access to therapy that is delivered more easily and conveniently. Commercially available for treatment of early stage breast cancer, endometrial, skin and surface indications, the Axxent System is also cleared for use in the treatment of surface cancers or conditions where radiation therapy is indicated.

"We were pleased to have the Axxent System included in the R&D 100, but to be named by the editors as the most innovative new product of the year is a testament to the hard work and dedication of the entire Xoft organization to bring this critical cancer treatment to market," said Michael Klein, president and CEO of Xoft. "Combined with growing utilization of Electronic Brachytherapy for the treatment of breast and endometrial cancers, this continues to validate the paradigm shifting capabilities of this innovative technology."

To learn more about the R&D 100 Awards, visit www.RDmag.com.

About Xoft, Inc.

Xoft, founded in 1998, develops Electronic Brachytherapy (eBx) systems based upon miniaturized X-ray tube technology for the practice of radiation oncology in virtually any clinical setting, eliminating the need for heavily shielded environments. Xoft provides a "point of care model" that is patient centric and accessible to a broader spectrum of patients and their physicians. The Axxent treatment platform provides a therapeutic dose of radiation directly to the region at risk with minimal radiation exposure to surrounding healthy tissue and without the complex handling, resource logistics and costs associated with using radioactive isotopes. Xoft aligns with the Nuclear Regulatory Commission's (NRC) directive to seek alternatives for radioactive medical isotopes. Commercially available for treatment of early stage breast cancer, endometrial, skin and surface indications, the Axxent(R) Electronic Brachytherapy System is also cleared for use in the treatment of other cancers or conditions where radiation therapy is indicated. For more information, visit www.xoftinc.com.

Axxent is a registered trademark of Xoft, Inc.


'/>"/>
SOURCE Xoft, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BD Named to 100 Best Corporate Citizens List by CRO Magazine
2. Scientology Magazine Earns Religion Communicators Council Award
3. SOBeFiT Magazine Wins Best Magazine Launch Party at 2009 FAME Awards
4. Quest Diagnostics Again Named to FORTUNE Magazines Worlds Most Admired Companies List
5. FORTUNE Magazine Ranks DaVita #1 Health Care Medical Facility in Innovation, Investment and Quality
6. The National Association of People with AIDS (NAPWA) and POZ Magazine Partner to Launch The Denver Principles Project
7. Lindt & Sprungli and Cookie Magazine Team up to Honor Lindt Unsung Heroes of Autism
8. Solos Endoscopy, Inc.s Breast Endoscopy System Featured in January Issue of Outpatient Surgery Magazine
9. How to Stay Healthy on a Budget: 31 Money-saving Tips From Natural Solutions Magazine
10. Solos Endoscopy, Inc.s MammoView(TM) Featured in December Issue of Surgical Products Magazine
11. Samplify Systems SAM1600 Family of Analog/Digital Converters Named Finalist in EDN Magazines 19th Annual Innovation Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
Breaking Medicine Technology: